Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) EBITDA Margin (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of EBITDA Margin data on record, last reported at 67319.01% in Q4 2025.

  • For Q4 2025, EBITDA Margin fell 6314318.0% year-over-year to 67319.01%; the TTM value through Dec 2025 reached 16727.83%, down 1447916.0%, while the annual FY2025 figure was 16727.83%, 1447916.0% down from the prior year.
  • EBITDA Margin reached 67319.01% in Q4 2025 per CLDX's latest filing, down from 6661800.0% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 6661800.0% in Q3 2025 and bottomed at 67319.01% in Q4 2025.
  • Average EBITDA Margin over 5 years is 323264.84%, with a median of 5201.99% recorded in 2021.
  • The widest YoY moves for EBITDA Margin: up 666301006bps in 2025, down -6314318bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 6228.14% in 2021, then soared by 75bps to 1557.04% in 2022, then surged by 34bps to 1019.92% in 2023, then plummeted by -309bps to 4175.83% in 2024, then tumbled by -1512bps to 67319.01% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 67319.01% in Q4 2025, 6661800.0% in Q3 2025, and 7784.79% in Q2 2025.